Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Outlook Therapeutics Inc (OTLK)

Outlook Therapeutics Inc (OTLK)
1.4400 x 4 1.5000 x 6
Post-market by (Cboe BZX)
1.5000 +0.0300 (+2.04%) 04/22/25 [NASDAQ]
1.4400 x 4 1.5000 x 6
Post-market 1.5000 unch (unch) 18:06 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.4300
Day High
1.5300
Open 1.4700
Previous Close 1.4700 1.4700
Volume 296,600 296,600
Avg Vol 376,525 376,525
Stochastic %K 91.47% 91.47%
Weighted Alpha -68.52 -68.52
5-Day Change +0.1100 (+7.91%) +0.1100 (+7.91%)
52-Week Range 0.8700 - 9.2899 0.8700 - 9.2899
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 47,065
  • Shares Outstanding, K 32,017
  • Annual Sales, $ 0 K
  • Annual Income, $ -75,370 K
  • EBIT $ -83 M
  • EBITDA $ -83 M
  • 60-Month Beta 0.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 400.39% ( +114.83%)
  • Historical Volatility 71.82%
  • IV Percentile 91%
  • IV Rank 54.94%
  • IV High 703.98% on 01/24/25
  • IV Low 30.26% on 09/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 68
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 3,173
  • Open Int (30-Day) 3,180

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.55
  • Number of Estimates 3
  • High Estimate -0.43
  • Low Estimate -0.61
  • Prior Year -1.55
  • Growth Rate Est. (year over year) +64.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0600 +41.51%
on 04/07/25
Period Open: 1.5100
1.5500 -3.23%
on 03/24/25
-0.0100 (-0.66%)
since 03/21/25
3-Month
1.0600 +41.51%
on 04/07/25
Period Open: 2.0900
2.2600 -33.63%
on 01/31/25
-0.5900 (-28.23%)
since 01/22/25
52-Week
0.8700 +72.41%
on 11/27/24
Period Open: 8.0900
9.2899 -83.85%
on 04/30/24
-6.5900 (-81.46%)
since 04/22/24

Most Recent Stories

More News
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

OTLK : 1.5000 (+2.04%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

OTLK : 1.5000 (+2.04%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

OTLK : 1.5000 (+2.04%)
OTLKW : 0.03 (-1.96%)
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

- Access video webcasts from the first wave of participating companies here

AKTX : 1.3600 (+6.25%)
AREC : 1.1400 (-7.32%)
OTLK : 1.5000 (+2.04%)
AMIX : 1.8800 (+5.62%)
CNSP : 0.8920 (-0.77%)
PALI : 0.6889 (-2.73%)
NVNO : 2.61 (+7.85%)
HURA : 4.08 (-2.86%)
GRI : 1.4500 (-0.68%)
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

OTLK : 1.5000 (+2.04%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

OTLK : 1.5000 (+2.04%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

OTLK : 1.5000 (+2.04%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

OTLK : 1.5000 (+2.04%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

OTLK : 1.5000 (+2.04%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

OTLK : 1.5000 (+2.04%)
OTLKW : 0.03 (-1.96%)

Business Summary

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as...

See More

Key Turning Points

3rd Resistance Point 1.6433
2nd Resistance Point 1.5867
1st Resistance Point 1.5433
Last Price 1.5000
1st Support Level 1.4433
2nd Support Level 1.3867
3rd Support Level 1.3433

See More

52-Week High 9.2899
Fibonacci 61.8% 6.0735
Fibonacci 50% 5.0799
Fibonacci 38.2% 4.0864
Last Price 1.5000
52-Week Low 0.8700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro